A Phase I Study of BIIB015 in Relapsed/Refractory Solid Tumors

Inclusion Criteria * Age 18 years or older at the time of informed consent. * Solid tumors that are relapsed or refractory to at least 1 prior anti-cancer systemic therapy and for which no standard therapy exists. * ECOG Performance Status \</= 2. Exclusion Criteria * History of keratoconjunctivitis, open or closed angle glaucoma, or "dry eye" disease. * New York Heart Association (NYHA) Grade II or greater congestive heart failure. * History of myocardial infarction within 6 months prior to Day 1. * Presence of \>/= Grade 2 peripheral neuropathy. * Known presence of central nervous system or brain metastases. * Prior therapy with a conjugated or unconjugated maytansine derivative.